Skip to main content
. 2015 Apr 12;6(2):321–328. doi: 10.14740/wjon912e

Table 5. Clinical-Pathological Parameters of CML Patients.

No. %
Patients 100 100%
controls 100 100%
Males 65 65%
Female 35 35%
CP-CML 50 50%
AP-CML 25 25%
BC-CML 25 25%
Imatinib 100 100%
MMR 52 52%
No MR 48 48%
MHR 50 50%
Minor HR 10 10%
Loss HR 40 40%
Age > 45 36 36%
Age < 45 64 64%
Thrombocytopenia 50 50%
No thrombocytopenia 50 50%